Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H14N6O2 |
| Molecular Weight | 346.3428 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(N)=C2N=C(C3=CC=CC(O)=C3)C(=NC2=N1)C4=CC(O)=CC=C4
InChI
InChIKey=UJIAQDJKSXQLIT-UHFFFAOYSA-N
InChI=1S/C18H14N6O2/c19-16-15-17(24-18(20)23-16)22-14(10-4-2-6-12(26)8-10)13(21-15)9-3-1-5-11(25)7-9/h1-8,25-26H,(H4,19,20,22,23,24)
| Molecular Formula | C18H14N6O2 |
| Molecular Weight | 346.3428 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
TG-100115 is a potent dual inhibitor of PI3K-gamma and PI3K-delta. TG-100115 has broad anti-inflammatory activities. TG-100115 provided potent cardioprotection, reducing infarct development and preserving myocardial function. In murine models of asthma and acute stages of chronic obstructive pulmonary disease, aerosolized TG100-115 demonstrated not only markedly inhibited anti-inflammatory activity but also, in the case of the asthma model, improved functional outcome for the test animals. TG-100115 can be used as a potent TRPM7 kinase inhibitor and a potent inhibitor of breast cancer cell migration.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3130 |
235.0 nM [IC50] | ||
Target ID: CHEMBL3267 |
83.0 nM [IC50] | ||
Target ID: CHEMBL1250412 |
1.07 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9.5 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31357893 |
30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
TG100-115 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
45.8 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31357893 |
30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
TG100-115 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31357893 |
30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
TG100-115 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion. | 2017-04 |
|
| Potency and pharmacokinetics of broad spectrum and isoform-specific p110γ and δ inhibitors in cancers. | 2016 |
|
| Phosphoinositide 3-kinase δ/γ inhibition does not prevent concanavalin A-induced hepatitis. | 2013-11 |
|
| Comprehensive analysis of kinase inhibitor selectivity. | 2011-10-30 |
|
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | 2010-11-24 |
|
| Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. | 2009-03 |
|
| Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. | 2007-09-06 |
|
| Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. | 2007-04 |
|
| Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. | 2006-12-26 |
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:33:59 GMT 2025
by
admin
on
Mon Mar 31 22:33:59 GMT 2025
|
| Record UNII |
7ACH1U1E2M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10427712
Created by
admin on Mon Mar 31 22:33:59 GMT 2025 , Edited by admin on Mon Mar 31 22:33:59 GMT 2025
|
PRIMARY | |||
|
DTXSID20218009
Created by
admin on Mon Mar 31 22:33:59 GMT 2025 , Edited by admin on Mon Mar 31 22:33:59 GMT 2025
|
PRIMARY | |||
|
677297-51-7
Created by
admin on Mon Mar 31 22:33:59 GMT 2025 , Edited by admin on Mon Mar 31 22:33:59 GMT 2025
|
PRIMARY | |||
|
7ACH1U1E2M
Created by
admin on Mon Mar 31 22:33:59 GMT 2025 , Edited by admin on Mon Mar 31 22:33:59 GMT 2025
|
PRIMARY | |||
|
DB05552
Created by
admin on Mon Mar 31 22:33:59 GMT 2025 , Edited by admin on Mon Mar 31 22:33:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
